Tongji Hospital

Researchers

• LXLimin Xia

Running trials

• Not yet recruiting

  Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A

  NCT06136507· Phase 3· Hangzhou Gensciences Biopharmaceutical Co., Ltd.· Source

• Not yet recruiting

  A Clinical Study to Evaluate the Safety and Efficacy of GT802 Injection in the Treatment of Refractory Generalized Myasthenia Gravis

  NCT07917923· Early phase 1· Daishi Tian· Source

• Not yet recruiting

  ACT201 Injection in Participants With Chronic Hepatitis B (CHB) on Nucleos(t)Ide Analog Therapy - Phase Ib

  NCT07929805· Phase 1· Xiamen Amoytop Biotech Co., Ltd.· Source

• Not yet recruiting

  Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer

  NCT07821606· Phase 3· Hansoh BioMedical R&D Company· Source

• Not yet recruiting

  Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer

  NCT07781150· Phase 2· Tongji Hospital· Source

• Not yet recruiting

  A Clinical Study to Evaluate the Safety and Efficacy of GT802 Injection in the Treatment of Relapsing/Refractory Multiple Sclerosis

  NCT07748637· Early phase 1· Daishi Tian· Source

• Recruiting

  Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure

  NCT07575672· Phase 3· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• Not yet recruiting

  AI-Guided Surveillance and Curative Salvage of Recurrence After Hepatocellular Carcinoma Resection or Ablation

  NCT07732504· Tongji Hospital· Source

• Not yet recruiting

  A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).

  NCT07784101· Phase 3· Beijing InnoCare Pharma Tech Co., Ltd.· Source

• Not yet recruiting

  A Study of HRS-4729 Injection in Participants With Type 2 Diabetes

  NCT07843862· Phase 2· Fujian Shengdi Pharmaceutical Co., Ltd.· Source

• Not yet recruiting

  AI-Guided First-Line Immunotherapy Selection in Unresectable Hepatocellular Carcinoma

  NCT07729618· Tongji Hospital· Source

• Recruiting

  Safety, Efficacy and Pharmacokinetics of TT00420 Tablets Combined With Novel Endocrine Therapy in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)

  NCT07871110· Phase 2· TransThera Sciences (Nanjing), Inc.· Source

• Recruiting

  A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

  NCT07795346· Phase 3· Antengene Biologics Limited· Source

• Not yet recruiting

  A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma

  NCT07632235· Phase 1/2· Shanghai 6th People's Hospital· Source

• Not yet recruiting

  Response-Guided Bladder Preservation With Trastuzumab Rezetecan, Adebrelimab, and Concurrent Bladder Radiotherapy in HER2-Expressing Muscle-Invasive Bladder Cancer

  NCT07865611· Phase 2· Tongji Hospital· Source

• Recruiting

  A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) Expression

  NCT07412262· Phase 2· Guangdong Association of Clinical Trials· Source

• Recruiting

  A Study to Evaluate the Preliminary Efficacy and Safety of Terfenadine in Patients With Relapsing-Remitting Multiple Sclerosis

  NCT07827716· Phase 2· Chuan Qin· Source

• Recruiting

  The Efficacy and Safety of Inpegsomatropin Injection in Children With Turner Syndrome (TS) and Short Stature

  NCT07614152· Phase 3· Xiamen Amoytop Biotech Co., Ltd.· Source

• Not yet recruiting

  Study on the Impact of Decolonization Treatment of Pneumocystis Jirovecii on the Frequency of Acute Exacerbation in COPD

  NCT07665359· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• Not yet recruiting

  Neoadjuvant PD-1 Inhibitor Plus SOX Chemotherapy With or Without Short-Course Radiotherapy for Locally Advanced Upper Gastric or GEJ Adenocarcinoma

  NCT07674342· Tongji Hospital· Source

• Recruiting

  Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

  NCT07555938· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS9531 Injection in Adolescents With Obesity

  NCT07559136· Phase 1· Fujian Shengdi Pharmaceutical Co., Ltd.· Source

• Recruiting

  A Single-arm, Multicenter Clinical Study of Iparomlimab and Toripalimab in Combination With Bevacizumab and Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer

  NCT07619235· Phase 4· Xianglin Yuan· Source

• Recruiting

  Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients

  NCT07663253· Shanghai Zhongshan Hospital· Source

• Not yet recruiting

  Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer

  NCT07537946· Phase 3· Tongji Hospital· Source

• Recruiting

  RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

  NCT07413939· Phase 2/3· Hoffmann-La Roche· Source

• Recruiting

  Minocycline After Successful Endovascular Thrombectomy Recanalization in Acute Anterior Circulation Large Vessel Occlusion (ATTRACTION-MINOA)

  NCT07594314· Phase 2/3· Xiang Luo· Source

• Recruiting

  Minocycline After Successful Endovascular Thrombectomy Recanalization in Posterior Circulation Arterial Occlusion (ATTRACTION-MINOP)

  NCT07594301· Phase 2/3· Xiang Luo· Source

• Recruiting

  A Clinical Study of Cizutamig in Thyroid Eye Disease

  NCT07597200· Phase 1· Candid Therapeutics· Source

• Not yet recruiting

  Denosumab Strategy for Liver Cancer With Bone Metastases

  NCT07537972· Phase 2· Tongji Hospital· Source

• Not yet recruiting

  Efficacy and Safety of Firsekibart in the Treatment of Systemic Sclerosis

  NCT07502105· Tongji Hospital· Source

• Not yet recruiting

  Clinical Study on the Preservation of Ovarian Function in Patients With Aplastic Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation Using Goserelin

  NCT07552506· Union Hospital, Tongji Medical College, Huazhong University of Science and Technology· Source

• Not yet recruiting

  Surgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases

  NCT07537959· Tongji Hospital· Source

• Recruiting

  Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.

  NCT07526493· Phase 1· Tongji Hospital· Source

• Recruiting

  Human Umbilical Cord Mesenchymal Stem Cell Injection for Diabetic Nephropathy

  NCT07822152· Phase 1· Tongji Hospital· Source

• Not yet recruiting

  Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML

  NCT07486479· Phase 3· The First Affiliated Hospital of Soochow University· Source

• Not yet recruiting

  EUS-guided CTCs + Multi-omics: Predicting Pancreatic Cancer Recurrence and Metastases

  NCT07448376· Huazhong University of Science and Technology· Source

• Recruiting

  Efficacy of Acupuncture-Mesalazine Combination Therapy in Ulcerative Colitis.

  NCT07389824· Qin Yu· Source

• Recruiting

  Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer

  NCT07392541· Phase 1/2· Tongji Hospital· Source

• Recruiting

  Prospective Validation of an AI Model for Predicting Liver Metastasis in Colorectal Cancer

  NCT07392567· Tongji Hospital· Source

• Recruiting

  Postoperative Radiotherapy for Early-stage Oral Tongue Squamous Cell Carcinoma Patients With Risk Factors: a Prospective, Multicenter, Randomized Controlled, Open-labelled Trial

  NCT07402525· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• Not yet recruiting

  A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma（LB2505-0001）

  NCT07399444· Early phase 1· Institute of Hematology & Blood Diseases Hospital, China· Source

• Not yet recruiting

  ACE1831 in Adult Subjects With Relapsed/Refractory Systemic Lupus Erythematosus （SLE）

  NCT07314567· Tongji Hospital· Source

• Recruiting

  Prospective Clinical Database Construction for Liver Cancer Diagnosis and Treatment

  NCT07587216· Tongji Hospital· Source

• Active, not recruiting

  Desvenlafaxine for Preventive Treatment of Frequent Migraines

  NCT07385755· Tongji Hospital· Source

• Recruiting

  Construction of AI Model for Precision Imaging Diagnosis of Cranial Diseases

  NCT07446842· Tongji Hospital· Source

• Not yet recruiting

  TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension

  NCT07350070· Phase 2· Tongji Hospital· Source

• Not yet recruiting

  Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC

  NCT07350824· Tongji Hospital· Source

• Recruiting

  Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma

  NCT07154082· Phase 2· Wei Zhang· Source

• Recruiting

  Intra-arterial Recombinant Human Tenecteplase Tissue-type Plasminogen Activator (rhTNK-tPA) Thrombolysis for Acute Medium Vessel Occlusion

  NCT07302854· Phase 2/3· Xiang Luo· Source

Showing 50 of 235.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Liver and biliary tract cancer35 recruiting
• Lung cancer16 recruiting
• Gastric and oesophageal cancer11 recruiting
• Pancreatic cancer11 recruiting
• Childhood cancers8 recruiting
• Colorectal cancer8 recruiting
• Stroke8 recruiting
• Multiple myeloma7 recruiting
• Bladder cancer6 recruiting
• Lupus (SLE)6 recruiting
• Cervical cancer5 recruiting
• Hepatitis B5 recruiting
• Multiple sclerosis5 recruiting
• Myasthenia gravis5 recruiting
• Endometrial cancer4 recruiting
• High blood pressure4 recruiting
• Ovarian cancer4 recruiting
• Type 2 diabetes4 recruiting
• Alzheimer disease3 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)3 recruiting
• Coronary artery disease3 recruiting
• Heart failure3 recruiting
• Neuromyelitis optica (NMOSD)3 recruiting
• Acute lymphoblastic leukaemia2 recruiting
• Acute myeloid leukaemia2 recruiting
• Chronic kidney disease2 recruiting
• Crohn's disease2 recruiting
• Dermatomyositis and polymyositis (myositis)2 recruiting
• Diffuse large B-cell lymphoma2 recruiting
• Fatty liver disease (MASLD/MASH)2 recruiting
• Head and neck cancer2 recruiting
• Metastatic breast cancer2 recruiting
• Obesity2 recruiting
• Prostate cancer2 recruiting
• Sarcoma2 recruiting
• Ulcerative colitis2 recruiting
• ALS (motor neurone disease)1 recruiting
• Amyloidosis1 recruiting
• ANCA-associated vasculitis1 recruiting
• Ankylosing spondylitis1 recruiting
• Aplastic anaemia1 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Atrial fibrillation1 recruiting
• Bronchiectasis1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Coeliac disease1 recruiting
• COPD1 recruiting
• Cytomegalovirus infection1 recruiting
• Dilated cardiomyopathy1 recruiting
• Graves' disease and hyperthyroidism1 recruiting
• Haemophilia1 recruiting
• IgA nephropathy1 recruiting
• Kidney cancer1 recruiting
• Liver cirrhosis1 recruiting
• Mantle cell lymphoma1 recruiting
• Migraine1 recruiting
• Myelodysplastic syndromes1 recruiting
• Neuroblastoma1 recruiting
• Neuroendocrine tumours1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Thyroid cancer1 recruiting
• Turner syndrome1 recruiting
• Type 1 diabetes1 recruiting
• Vascular dementia1 recruiting

Closed trials

• Completed

  Postoperative Radiotherapy and Lymph Node Dissection After Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma

  NCT07705412· Tongji Hospital· Source

• Completed

  Heparin for RAO Post-Transradial Angiography in AIS

  NCT07162064· Phase 3· Xiang Luo· Source

• Completed

  Efficacy and Safety of Early Combined Therapy With PCSK9 Inhibitors and Statins in Acute Ischemic Stroke

  NCT06696820· Phase 2/3· Xiang Luo· Source

• Completed

  Correlation Between Body Composition and Pathologic Grade/Prognosis in GEP-NENs: A Retrospective Study

  NCT06983106· Tongji Hospital· Source

• Completed

  HTA of NIVATS Based on RWE

  NCT06574295· Fudan University· Source

• Completed

  ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer

  NCT06498479· Phase 3· Hansoh BioMedical R&D Company· Source

• Completed

  An Observational Study to Assess Real-World Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in China

  NCT06421740· AbbVie· Source

• Completed

  Optimizing Early Nutrition Support in Severe Stroke-2

  NCT05998902· Phase 3· Wen Jiang-3· Source

• Completed

  A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

  NCT06108544· Phase 3· Takeda· Source

• Completed

  Observational Study of Adult Participants With Diabetic Macular Edema and Suboptimal Response to Anti-Vascular Endothelial Growth Factor Treated With Dexamethasone Intravitreal Implant

  NCT05978622· AbbVie· Source

• Completed

  Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis

  NCT06093191· Phase 4· Jin-Fu Xu· Source

• Completed

  Precision Recurrence Risk Assessment in Early-stage Hepatocellular Carcinoma

  NCT07030842· Tongji Hospital· Source

• Completed

  Evaluation of ClearLLab LS Screening Panel

  NCT05819762· Beckman Coulter, Inc.· Source

• Completed

  Tissue Kallikrein Protect Against Ischemic Stroke

  NCT06422572· Qin Zhang· Source

• Completed

  Postoperative Pain for Patients After TA-BSM

  NCT06433089· Wenlong Yao (101480)· Source

• Completed

  Study of Telitacicept in Generalized Myasthenia Gravis

  NCT05737160· Phase 3· RemeGen Co., Ltd.· Source

• Completed

  A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A

  NCT05707351· Phase 3· Takeda· Source

• Completed

  A Real-world Study: Analysis of the Efficacy of Antiviral Therapy in CHB Patients Over 30 Years Old, HBV DNA Positive and ALT Normal

  NCT07637214· Tongji Hospital· Source

• Completed

  A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

  NCT05687032· Phase 4· Pfizer· Source

• Completed

  TESTING -ON Post-Trial ObservatioNal Cohort Study

  NCT05434325· The George Institute· Source

• Completed

  Exercise Prehabilitation for Patients With NSCLC Before Surgery

  NCT05608759· Tongji Hospital· Source

• Completed

  A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

  NCT05523167· Phase 2/3· argenx· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

  NCT05400369· Phase 4· Daiichi Sankyo· Source

• Completed

  Artificial Intelligence in EUS for Diagnosing Pancreatic Solid Lesions

  NCT05476978· Huazhong University of Science and Technology· Source

• Completed

  A Research Study Investigating Nonacog Beta Pegol (N9-GP) for Treatment and Prevention of Bleedings in Chinese People With Haemophilia B

  NCT05365217· Phase 3· Novo Nordisk A/S· Source

• Completed

  Anesthetic Management for TA-BSM in HOCM

  NCT06397092· Tongji Hospital· Source

• Completed

  A Clinical Study of DEB-TACE Combined With Surufatinib and Camrelizumab in the Treatment of Inoperable or Metastatic ICC

  NCT05236699· Phase 2· Tongji Hospital· Source

• Completed

  Recurrence Patterns and Cost-Effectiveness of Surgical Approaches in Early-Stage Hepatocellular Carcinoma

  NCT06776185· Chen Xiaoping· Source

• Completed

  Validation of a Model for Predicting Anastomotic Leakage

  NCT05646290· Jichao Qin· Source

• Completed

  A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors

  NCT05053139· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS)

  NCT05083923· Phase 3· Biogen· Source

• Completed

  A Study of Elecsys® Troponin T hs Gen 6 in Participants With Symptoms of Acute Coronary Syndrome

  NCT06734117· Hoffmann-La Roche· Source

• Completed

  Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD

  NCT05003245· Phase 3· Shanghai Henlius Biotech· Source

• Terminated

  A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis

  NCT04963270· Phase 3· Hoffmann-La Roche· Source

• Completed

  Artificial Intelligence Assists Surgeons' Decision Making

  NCT04999007· Jichao Qin· Source

• Completed

  ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

  NCT05021835· Phase 3· Novo Nordisk A/S· Source

• Terminated

  AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer

  NCT04993391· Phase 1/2· Suzhou Junjing BioSciences Co., Ltd.· Source

• Terminated

  To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

  NCT04551053· Phase 3· Incyte Corporation· Source

• Terminated

  A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma

  NCT04735575· Phase 1/2· Shanghai EpimAb Biotherapeutics Co., Ltd.· Source

• Completed

  Real-world Study on Edoxaban Treatment for Patients With Non-valvular Atrial Fibrillation in China

  NCT04747496· Daiichi Sankyo· Source

• Terminated

  A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

  NCT04501614· Phase 1/2· Takeda· Source

• Completed

  Adjuvant PD-1 Inhibitor for Patients With Early-stage Hepatocellular Carcinoma Following Microwave Ablation

  NCT06248554· Chen Xiaoping· Source

• Completed

  A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1

  NCT03776071· Phase 3· Denovo Biopharma LLC· Source

• Completed

  The Number of Mesogastria Containing Metastatic Lymph Nodes Predicts Gastric Cancer Prognosis

  NCT06697821· Jichao Qin· Source

• Completed

  Combination of ETV, TQ-A3334 and TQ-B2450 for CHB (Neptune Study)

  NCT04202653· Phase 2· Tongji Hospital· Source

• Completed

  A Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B

  NCT04846491· Phase 3· Xiamen Amoytop Biotech Co., Ltd.· Source

• Completed

  Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)

  NCT03748953· Phase 3· Millennium Pharmaceuticals, Inc.· Source

• Completed

  Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment

  NCT04085276· Phase 3· Shanghai Junshi Bioscience Co., Ltd.· Source

• Withdrawn

  Efficacy and Safety of Highland Barley Diet on Glucose Variability in Patients With Type 1 Diabetes Mellitus

  NCT03766334· Huazhong University of Science and Technology· Source

• Completed

  Immunomodulatory Therapy & VSA

  NCT06696807· Dao Wen Wang· Source

Showing 50 of 55.

Conditions

Diseases this institution publishes on or runs trials for.

• Liver and biliary tract cancer180 works · 46 trials
• Lung cancer119 works · 32 trials
• Prostate cancer51 works · 4 trials
• Gastric and oesophageal cancer47 works · 17 trials
• Ovarian cancer43 works · 7 trials
• Osteoarthritis38 works · 0 trials
• Bladder cancer37 works · 7 trials
• Cervical cancer36 works · 8 trials
• Acute myeloid leukaemia29 works · 2 trials
• Pancreatic cancer28 works · 15 trials
• COPD26 works · 2 trials
• Glioblastoma24 works · 1 trial
• Myocarditis24 works · 0 trials
• Acute lymphoblastic leukaemia18 works · 4 trials
• Hypertrophic cardiomyopathy17 works · 2 trials
• Endometriosis14 works · 0 trials
• Hepatitis B13 works · 8 trials
• IgA nephropathy13 works · 2 trials
• Diffuse large B-cell lymphoma13 works · 3 trials
• Hodgkin lymphoma12 works · 0 trials
• Idiopathic pulmonary fibrosis12 works · 0 trials
• Polycystic ovary syndrome11 works · 0 trials
• Myasthenia gravis10 works · 9 trials
• Myelodysplastic syndromes8 works · 1 trial
• Neuromyelitis optica (NMOSD)6 works · 3 trials
• Liver cirrhosis6 works · 1 trial
• Immune thrombocytopenia (ITP)5 works · 0 trials
• Sjögren's disease4 works · 0 trials
• Trigeminal neuralgia4 works · 0 trials
• Aplastic anaemia4 works · 1 trial